Related Experiment Video
Updated: Aug 4, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Chronic Hepatitis B Virus: What an Internist Needs to Know: Serologic Diagnosis, Treatment Options, and Hepatitis B
1Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA.
Insights
Chronic hepatitis B virus (HBV) infection impacts millions globally, leading to severe liver disease. Antiviral therapies can suppress viral replication and reduce the risk of liver events in patients with active infections.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Chronic hepatitis B virus (HBV) infection affects 292 million worldwide and 1.6 million in the U.S.
- HBV is linked to significant morbidity and mortality from cirrhosis and hepatocellular carcinoma.
- Disproportionately affects individuals from HBV-endemic regions like sub-Saharan Africa and the Asian-Pacific.
Purpose of the Study:
- To summarize the diagnosis and treatment of chronic HBV infection.
- To highlight the impact of antiviral therapy on liver events.
Main Methods:
- Diagnosis confirmed by positive HBsAg and detectable HBV DNA.
- Treatment considered for patients with immunoactive disease (elevated HBV DNA and serum ALT).
Main Results:
- Antiviral therapies include peg-interferon or oral nucleos(t)ide analogues.
- These treatments suppress HBV viral replication.
- Associated with a decreased risk for liver events such as cirrhosis and hepatocellular carcinoma.
Conclusions:
- Chronic HBV is a major global health concern requiring effective management.
- Antiviral therapy is crucial for controlling viral load and preventing severe liver complications.
- Early diagnosis and treatment can mitigate the long-term consequences of HBV infection.
Abstract:
Chronic hepatitis B virus (HBV) infection is a bloodborne infection which affects approximately 1.6 million persons in the U.S. and 292 million persons worldwide and is associated with significant morbidity and mortality due to cirrhosis and hepatocellular carcinoma. HBV disproportionately affects foreign-persons from endemic regions such as sub-Saharan Africa and the Asian-Pacific region. Chronic HBV is diagnosed with positive HBsAg and detectable HBV DNA. Patients with immunoactive disease (elevated HBV DNA and serum ALT) may require antiviral therapy with peg-interferon or oral nucleos(t)ide analogues which suppress viral replication, and are associated with a decreased risk for liver events.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Related Concept Videos
Retrovirus Life Cycles
Chronic Pancreatitis II: Collaborative Care
Assessment:
Acute Pancreatitis II: Clinical Manifestations and Management